Deep Pharma Intelligence (DPI) is a leading strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, BioTech, and Healthcare Tech industries.
DPI is producing regular analytical reports on major areas of high-potential in the pharmaceutical and healthcare industries, maintaining ratings of companies and governments based on their innovation potential and business activity in the BioTech space, and providing strategic consulting and investment intelligence services to top-tier clients, including major investment funds and banks, family offices, insurance companies, government organizations, and big pharma companies among others.
The company is a joint venture between the two highly specialized UK-based market intelligence hubs in Pharma / BioTech space:
BPT Analytics (BiopharmaTrend) - a rapidly growing analytical portal and media resource, dedicated to tracking emerging companies (startups/scaleups), innovations, investments, and trends in the pharma and biotech space.
BiopharmaTrend’s reports and articles were referenced by Deloitte, Forbes, and other high profile media and consulting companies.
BiopharmaTrend is a media partner to a number of top-tier conferences and symposia in preclinical and clinical research, and healthcare research.
Pharma Division of Deep Knowledge Analytics (PD-DKA), a specialized subsidiary of Deep Knowledge Analytics (DKA), the leading analytical entity specifically focused on deep intelligence of the high-potential areas in the pharma industry, including artificial intelligence (AI) for drug discovery sector.
Deep Knowledge Analytics Pharma Division serves as the main source of investment intelligence and analytics for AI-Pharma, a specialized index hedge fund for the AI in the drug discovery sector. PD-DKA’s insights are frequently covered by top media such as Forbes and the Financial Times, and are acknowledged by top pharma executives.
Recently, MIT named this division a top technology think-tank, acknowledging the AI ranking framework it developed.
Our range of proprietary services includes custom consulting projects, based on the specific customer needs, as well as a collection of pre-produced “ready-to-use” proprietary reports, produced by our research team, covering general trends and specific action ideas and strategy insights related to the most promising investment prospects (e.g. new technologies, BioTech startups), M&A prospects (e.g. pipeline development targets), and strategic growth ideas (trends profiling, industry overviews etc).